Payment overview · 2025
General Payments
$616.74
18 reported records · 7 companies
Healthcare provider profile · identity verified
Duane Dickens, MD
Allopathic & Osteopathic Physicians|Family Medicine · TROTWOOD, OH · NPI 1568401685
Verified facts
What the public records show
CMS Open Payments records show Duane Dickens, MD received $616.74 in general payments during 2025 across 18 reported records.
Novo Nordisk Inc accounted for 35.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $221.02 | 35.8% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $165.76 | 26.9% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $121.83 | 19.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $46.48 | 7.5% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.51 | 4.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.24 | 3.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.90 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $616.74 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $121.83 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $95.16 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $82.88 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $82.88 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $74.81 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $46.48 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.51 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $23.24 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.97 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.20 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 129 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 105 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
129 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
105 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
127 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 816 | 229 |
| Atorvastatin Calcium | Atorvastatin Calcium | 716 | 209 |
| Losartan Potassium | Losartan Potassium | 324 | 93 |
| Valsartan | Valsartan | 299 | 87 |
| Metoprolol Succinate | Metoprolol Succinate | 268 | 80 |
| Furosemide | Furosemide | 226 | 61 |
| Gabapentin | Gabapentin | 209 | 53 |
| Omeprazole | Omeprazole | 207 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 206 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 178 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 169 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 164 | 44 |
| Carvedilol | Carvedilol | 156 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 148 | 47 |
| Hydralazine Hcl | Hydralazine Hcl | 143 | 38 |
| Metformin Hcl Er | Metformin Hcl | 140 | 41 |
| Doxazosin Mesylate | Doxazosin Mesylate | 137 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 136 | 38 |
| Potassium Chloride | Potassium Chloride | 133 | 33 |
| Jardiance | Empagliflozin | 129 | 28 |
| Eliquis | Apixaban | 127 | 24 |
| Trazodone Hcl | Trazodone Hcl | 121 | 32 |
| Farxiga | Dapagliflozin Propanediol | 116 | 26 |
| Glimepiride | Glimepiride | 109 | 28 |
| Clonidine Hcl | Clonidine Hcl | 108 | 28 |
| Ozempic | Semaglutide | 105 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 101 | 18 |
| Klor-Con M20 | Potassium Chloride | 96 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 95 | 33 |
| Allopurinol | Allopurinol | 95 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 95 | 27 |
| Metformin Hcl | Metformin Hcl | 87 | 21 |
| Simvastatin | Simvastatin | 85 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 25 |
| Lisinopril | Lisinopril | 76 | 25 |
| Donepezil Hcl | Donepezil Hcl | 72 | 18 |
| Montelukast Sodium | Montelukast Sodium | 70 | 14 |
| Ibuprofen | Ibuprofen | 69 | 22 |
| Azelastine Hcl | Azelastine Hcl | 68 | 23 |
| Atenolol | Atenolol | 64 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 62 | 19 |
| Chlorthalidone | Chlorthalidone | 61 | 12 |
| Nifedipine Er | Nifedipine | 61 | 13 |
| Lorazepam | Lorazepam | 58 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 16 |
| Torsemide | Torsemide | 54 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 54 | 13 |
| Synthroid | Levothyroxine Sodium | 53 | 12 |
| Naproxen | Naproxen | 52 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 14 |
| Cefuroxime | Cefuroxime Axetil | 48 | 39 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 27 |
| Memantine Hcl | Memantine Hcl | 45 | 12 |
| Spironolactone | Spironolactone | 40 | 14 |
| Mirtazapine | Mirtazapine | 39 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 39 | suppressed |
| Ezetimibe | Ezetimibe | 38 | suppressed |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Trulicity | Dulaglutide | 38 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | suppressed |
| Pregabalin | Pregabalin | 36 | suppressed |
| Cilostazol | Cilostazol | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | 16 |
| Dutasteride | Dutasteride | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | 11 |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 30 | 19 |
| Methocarbamol | Methocarbamol | 29 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Calcitriol | Calcitriol | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 22 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Flavoxate Hcl | Flavoxate Hcl | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $616.74 · 18 records | Novo Nordisk Inc | CREON, JARDIANCE, Kerendia, LINZESS, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, Wegovy, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error